Pluri (NASDAQ:PLUR) Trading 0.8% Higher – Still a Buy?

Pluri Inc. (NASDAQ:PLUR) shot up 0.8% during mid-day trading on Thursday . The company traded as high as $2.45 and last traded at $2.38. 11,642 shares changed hands during mid-day trading, a decline of 35% from the average session volume of 17,922 shares. The stock had previously closed at $2.36.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pluri has a consensus rating of “Sell”.

Pluri Price Performance

The stock’s 50-day simple moving average is $3.12 and its 200 day simple moving average is $3.28. The stock has a market capitalization of $25.68 million, a P/E ratio of -0.53 and a beta of 0.64.

Pluri (NASDAQ:PLUR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.11. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.66 million.

Hedge Funds Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC acquired a new position in shares of Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is owned by hedge funds and other institutional investors.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.